

研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
青木大輔, 片瀧秀隆, 三上幹男	子宮頸癌	日本癌治療学会, 日本病理学会	領域横断的がん取扱い規約第1版	金原出版	日本	2019	235-251
青木大輔, 片瀧秀隆, 三上幹男	子宮体癌	日本癌治療学会, 日本病理学会	領域横断的がん取扱い規約第1版	金原出版	日本	2019	253-263
青木大輔, 片瀧秀隆, 三上幹男	卵巣腫瘍・卵管癌・腹膜癌	日本癌治療学会, 日本病理学会	領域横断的がん取扱い規約第1版	金原出版	日本	2019	265-281
(編集)		片瀧秀隆, 榎靖	JSAWI発 一冊でわかる婦人科腫瘍の画像診断 モダリティ・解剖・病理・診断・治療フォロアップ・ピットフォール	文光堂	日本	2019	
Motohara T, Katabuchi H.	Emerging role of CD44 variant 6 in driving the metastatic journey of ovarian cancer stem cells.	Katabuchi H, Ohba T, Motohara T.	Cell Biology of the Ovary	Springer		2018	73-88
Tashiro H, Katabuchi H.	Molecular Targeted Therapy for Epithelial Ovarian Cancer.	Katabuchi H, Ohba T, Motohara T.	Cell Biology of the Ovary	Springer		2018	153-166
(編集)		三上幹男, 永瀬智, 宇田川康博, 八重樫伸生, 片瀧秀隆	子宮体がん治療ガイドライン 2018年版	日本婦人科腫瘍学会 金原出版	日本	2018	
(編集)		Katabuchi H, Ohba T, Motohara T.	Cell Biology of the Ovary	Springer		2018	
宮原陽, 片瀧秀隆	卵巣癌・腹膜癌(卵巣がん診療ガイドライン2015年版(2015))	門脇孝, 小室一成, 宮地良樹	日常診療に活かす診療ガイドライン UP-TO-DATE 2018-2019	メジカルビュー社	日本	2018	908-912
本原剛志, 片瀧秀隆	腫瘍免疫	柴原浩章	実践よくわかる臨床生殖免疫学入門	中外出版社	日本	2018	23-32

宮原陽, 宇田川康博, 片瀨秀隆	癌治療ガイドラインの進歩	小西郁生	婦人科がん(第2版)-最新の研究動向-	日本臨床	日本	2018	70-75
Kawabata-Iwakawa R, Nishiyama M.	Next generation sequencing and bioinformatics.	Takiguchi Y	Molecular Targeted Therapy of Lung Cancer	Springer Nature Singapore	Singapore	2017	97-116
Motohara T, Katabuchi H.	Genomics in Gynecological Cancer: Future Perspective.	Konishi I.	Precision Medicine in Gynecology And Obstetrics	Springer		2017	9-22
		Katabuchi H.	Frontiers in Ovarian Cancer Science	Springer		2017	
本原剛志, 片瀨秀隆	婦人科疾患 卵巣腫瘍	猿田亨男, 北村惣一郎 総監修 青木大輔 監修	JMEDJ治療法便覧2016~私の治療~	日本医事新報社	日本	2017	1453-1454
田代浩徳, 片瀨秀隆	女性ホルモンとがん ホルモン依存性がん 子宮体がん	佐治重衡, 清水千佳子	チームで学女性がん患者のためのホルモンマネジメント	篠原出版	日本	2017	65-82
田代浩徳, 片瀨秀隆	女性ホルモンとがん ホルモン依存性がん 卵巣がん	佐治重衡, 清水千佳子	チームで学女性がん患者のためのホルモンマネジメント	篠原出版	日本	2017	83-97
宮原陽, 片瀨秀隆	卵巣癌・腹膜癌(卵巣がん診療ガイドライン2015年版(2015))	門脇 孝, 小室一成, 宮地良樹	日常診療に活かす診療ガイドライン UP-T0-DAT E 2018-2019	メディカルビュー社	日本	2017	908-912
		片瀨秀隆, 杉山徹, 三上芳喜, 榎本隆之	子宮頸癌取扱い規約 病理編 第4版	日本産科婦人科学会・日本病理学会、金原出版	日本	2017	
		片瀨秀隆, 杉山徹, 安田政実, 榎本隆之	子宮体癌取扱い規約 病理編 第4版	日本産科婦人科学会・日本病理学会、金原出版	日本	2017	

		三上幹男, 永瀬 智, 宇田川康博, 八重樫伸生, 片瀨秀隆	子宮頸癌治療ガイドライン2017年版	金原出版	日本	2017	
		片瀨秀隆, 森谷卓也	一冊でわかる婦人科腫瘍・疾患 周産期疾患, 生殖・内分泌疾患, 乳癌を含む	文光堂	日本	2017	

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takayama T, Yamaki C, Hayakawa M, Higashi T, Toh Y, Wakao F.	Development of a new tool for better social recognition of cancer information and support activities under the national cancer control policy in Japan.	J Public Health Manag Pract		in press	2020
Toh Y, Numasaki H, Tachimori Y, Uno T, Nemer Jingu K., Nemeroto K, Matsubara H.	Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.	Esophagus	17	25-32	2020
Toh Y, Yamamoto H, Miyata H, Gotoh M, Watanabe M, Matsubara H, Kakeji Y, Seto Y.	Significance of the board-certified surgeon systems and clinical practice guideline adherence to surgical treatment of esophageal cancer in Japan: a questionnaire survey of departments registered in the National Clinical Database.	Esophagus	16	362-370	2019

Nemoto K, Kawashiro S, <u>Toh Y</u> , Numasaki H, Tachimori Y, Uno T, Jingu K, Matsubara H.	Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.	Esophagus	17	122-126	2020
Jingu K, Numasaki H, <u>Toh Y</u> , Nemoto K, Uno T, Doki Y, Matsubara H.	Chemoradiotherapy and radiotherapy alone in patients with esophageal cancer aged 80 years or older based on the Comprehensive Registry of Esophageal Cancer in Japan.	Esophagus	in press		2020
Motoyama S, Yamamoto H, Miyata H, Yanai M, Yasuda T, Ohira M, Kajiyama Y, <u>Toh Y</u> , Watanabe M., Kakeji Y., Seto Y., Doki Y., Matsubara H.	Impact of certification status of the institute and surgeon on short-term outcomes after surgery for thoracic esophageal cancer: evaluation using data on 16,752 patients from the National Clinical Database in Japan.	Esophagus	17	41-49	2020
Uchihara T, Yoshida N, Baba Y, Nakashima Y, Kimura Y, Saeki H, Tsubakeno S, Sadanaga N, Ikebe M, Morita M, <u>Toh Y</u> , Nanasima A, Maehara Y, Baba H.	Esophageal Position Affects Short-Term Outcome After Minimally Invasive Esophagectomy: A Retrospective Multicenter Study.	World J Surg	44	831-837	2020
Motoyama S, Maeda E, Yanai M, Yasuda T, Ohira M, Doki Y, <u>Toh Y</u> , Higashi T, Matsubara H, Japanese Esophageal Society.	Appropriateness of the institute certification system for esophageal surgeons by the Japan Esophageal Society: evaluation of survival outcomes using data from the National Database of Hospital-Based Cancer Registries in Japan.	Esophagus	16	114-121	2019

Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsuura H, Muro K, Oyama T, <u>Toh Y</u> , Udagawa H, Uno T, Registration Committee for Esophageal Cancer of the Japan Esophageal Society.	Comprehensive registry of esophageal cancer in Japan, 2012.	Esophagus	16	221-245	2019
Kitagawa Y, Uno T, Oyama T, Kato K, Kadota H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, <u>Toh Y</u> , Doki Y, Naomoto Y, Nemoto K, Boko E, Matsuura H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M.	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1.	Esophagus	16	1-24	2019
Kitagawa Y, Uno T, Oyama T, Kato K, Kadota H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, <u>Toh Y</u> , Doki Y, Naomoto Y, Nemoto K, Boko E, Matsuura H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M.	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 2.	Esophagus	16	25-43	2019
Yamamoto M, Shimokawa M, Kawano H, Ohta M, Yoshida D, Minami K, Ikebe M, Morita M, <u>Toh Y</u> .	Benefits of laparoscopic surgery compared to open standard surgery for gastric carcinoma in elderly patients: propensity score-matching analysis.	Surg Endosc	33	510-519	2019

Yoshida N, Yamamoto H, Baba H, Miyata H, Watanabe M, <u>Toh Y</u> , Matsubara H, Kakeji Y, Seto Y.	Can Minimally Invasive Esophagectomy Replace Open Esophagectomy for Esophageal Cancer? Latest Analysis of 24,233 Esophagectomies From the Japanese National Clinical Database.	Ann Surg	in press		2019
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Shimizu H, Endo S, Natsugoe S, Doki Y, Hirata Y, Kobayashi J, Motomura N, Nakano H, Nishiida H, Okada M, Saiki Y, Saito A, Sato Y, Tanemoto K, <u>Toh Y</u> , Tsukihara H, Wakui S, Yokomise H, Masuda M, Yokoi K, Okita Y.	Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery.	Gen Thorac Cardiovasc Surg	67	377-411	2019
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, Endo S, Natsugoe S, Shimizu H, Doki Y, Hirata Y, Kobayashi J, Motomura N, Nakano K, Nishiida H, Okada M, Saiki Y, Saito A, Sato Y, Tanemoto K, <u>Toh Y</u> , Tsukihara H, Wakui S, Yokomise H, Yokoi K, Okita Y.	Thoracic and cardiovascular surgery in Japan during 2015 : Annual report by The Japanese Association for Thoracic Surgery.	Gen Thorac Cardiovasc Surg	66	581-615	2018

Yamaguchi.S, Morita.M, Yamamoto.M, Egashira.A, Kawano.H, Kinjo.N, Tsujita.E, Minami.K, Ikebe.M, Ikeda.Y, Kunitake.N, Toh.Y.	Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion.	Ann Surg Oncol	25	3280-3287	2018
Tachimori.Y, Ozawa.S, Numasaka.H, Ishihara.R, Matsubara.H, Muro.K, Oyama.T, Toh.Y, Udagawa.H, Uno.T.	Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2011.	Esophagus	15	127-152	2018
藤也寸志, 北川雄光, 丹黒章, 松原久裕	特別企画「診療ガイドラインの再評価-今後の方向性-」誌 食道癌診療ガイドラインのあり方に関する考察と今後の方向性	日本外科学会雑誌	119	569-571	2018
藤也寸志, 中司悠, 中ノ子智徳, 杉山雅彦, 太田光彦, 池部正彦	食道癌 / 新規治療開発研究.	日本臨床	食道癌 (第2版)	466-473	2018
Sugimachi.K, Ito.T, Moriyama.M, Toh.Y.	Subtotal Cholecystectomy as a Last Resort for Complicated Gallstone Disease.	J Am Coll Surg	226	201-202	2018
Miyazaki T, Kitagawa Y, Kugawano H, Kusano M, Oyama T, Muto M, Kikuchi H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Matsubara H, Yanagisawa, Uno T, Kato K, Yoshida M, Kawakubo H, Booka E, Kawamura O, Fukuchi M, Sakai M, Sohda M, Nakajima M.	Decreased risk of esophageal cancer owing to cigarette and alcohol cessation in smokers and drinkers: a systematic review and meta-analysis.	Esophagus	14	290-302	2017

Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsuura M, Muro K, Oyama T, <u>Toh Y</u> , Udagawa H, Uno T.	Comprehensive Registry of Esophageal Cancer in Japan 2010.	Esophagus	14	189-214	2017
Hasegawa K, Shimada M, <u>Nishiyama M</u> , et al. (外10名12番目).	A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer	Br J Cancer			2020 Jan 31. doi: 10.1038/s41416-020-0734-9. [Epub ahead of print]
Hirata K, Imamura M, <u>Nishiyama M</u> . (外17名20番目).	Current status of site-specific cancer registry system for the clinical researches: aiming for future contribution by the assessment of present medical care.	Int J Clin Oncol	24(9)	1161-1168	2019
Shimizu K, Gotto Y, <u>Nishiyama M</u> , et al. (外11名13番目).	Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors	Ann Thorac Surg	108(1)	235-243	2019
Ohtaki Y, Shimizu K, <u>Nishiyama M</u> , et al. (外16名19番目).	Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas	Oncotarget		in press	2019
Handa T, Katayama A, <u>Nishiyama M</u> , <u>Shirabe K</u> , et al. (外11名10番目, 12番目).	Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer	Int J Oncol.	54(3)	833-844	2019
Imamura M, Hirata K, <u>Nishiyama M</u> , et al. (外17名10番目)	Current status of projects for developing cancer-related clinical practice guidelines in Japan and recommendations for the future	Int J Clin Oncol	24(2)	189-195	2019

Horigome E, Fujieda M, Nishiyama M, et al. (外13名15番目).	Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling	Oncotarget	9(77)	34554-34566	2018
Gombodorj N, Yokobori T, Nishiyama M, Shirabe K, et al. (外11名12,13番目).	Current status of projects for developing cancer-related clinical practice guidelines in Japan and recommendations for the future	J Surg Oncol	118(1)	101-108	2018
Rokudai S, Li Y, Nishiyama M, et al. (外5名7番目).	STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis.	Proc Natl Acad Sci U S A	115(21)	E4806-E4814	2018
Kasahara N, Kaira K, Nishiyama M, et al. (外15名14番目).	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.	Lung Cancer	119	71-77	2018
Arai H, Nobusawa S, Nishiyama M, et al. (外10名10番目).	Myeloid sarcoma arising in malignant phyllodes tumor: clonal relationships revealed by comparative genome-wide analyses	Br J Haematol	181(2)	255-259	2018
Costanza B, Turtoi A, Bellahcène A, Nishiyama M, (外22名25番目).	Innovative methodology for the identification of soluble biomarkers in fresh tissues	Oncotarget	9(12)	10665-10680	2018
Nakamura H, Bono H, Hiyama K, Nishiyama M, (外8名7番目).	Differentiated embryonic chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions	PLoS One	13(2)	e0192136. doi:10.1371/journal.pone.0192136. eCollection	2018
Kaira K, Higuchi T, Naruse I, Nishiyama M, (外12名14番目).	Metabolic activity by 18F-FDG-PET/CT is predictive for early response after nivolumab in previously treated NSCLC	Eur J Nucl Med Mol Imaging	45(1)	56-66	2018
Blomme A, Van Simaey G, Dumont G, Nishiyama M, (外17名19番目).	Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases	Oncogene	37(9)	1237-1250	2018
Altan B, Kaira K, Watanabe A, Nishiyama M, Shirabe K, (外9名12番目14番目).	Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.	Cancer Chemother Pharmacol	81(1)	141-153	2018

佐々木治一郎, 相羽惠介, 矢野篤次郎, 富田尚裕, 片濑秀隆, 西山正彦, 北川雄光	日本癌治療学会認定 がん診療ネットワークナビゲーター	がん患者と対症療法	27(1)	48-49	2018
川端麗香, 西山正彦	新たながん医療の創生をめざして - Trans-OMICS Approach -	癌と化学療法	45(3)	405-411	2018
Bao P, Yokobori T, Altan B, Nishiyama M, (外16名19番目).	High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.	Ann Surg Oncol	24(13)	4017-4024	2017
Kumakura Y, Rokudai S, Iijima M, Nishiyama M, (外8名11番目).	Elevated expression of ΔNp63 in advanced esophageal squamous cell carcinoma.	Cancer Sci	108(11)	2149-2155	2017
Obayashi S, Horiguchi J, Higuchi T, Nishiyama M, (外9名11番目)	Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients.	Int J Oncol	51(3)	781-790	2017
Altan B, Kaira K, Okada S, Nishiyama M, (外8名11番目)	High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer.	Tumour Biol	39(7)	1010428317703817. doi: 10.1177/1010428317703817.	2017
Handa T, Katayama A, Yokobori T, Nishiyama M, (外11名14番目)	Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients.	J Surg Oncol	116(6)	706-715	2017
Bai T, Yokobori T, Altan B, Nishiyama M, (外16名17番目)	High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.	Br J Cancer	116(9)	1177-1185	2017
Tsukagoshi M, Araki K, Yokobori T, Nishiyama M, Shirabe K, (外7名10番目11番目)	Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.	Oncotarget	8(26)	42159-42172	2017

Otaka Y, Rokuda ai S, Kaira K, Nishiyama M. (外10名14番目)	STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.	Clin Cancer Res	23(13)	3442-3452	2017
Blomme A, Costanza B, de Tullio P, Nishiyama M. (外23名25番目)	Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer	Oncogene	36(15)	2116-2130	2017
矢野篤次郎, 相羽 恵介, 佐々木治一 郎, 富田尚裕, 片 淵秀隆, 西山正彦, 北川雄光	一般社団法人日本癌治療学会 認定がん医療ネットワーク ナビゲーター制度について	病院経営master	6(2)	99-105	2017
Yoneda M, Imamura R, Nitta a H, Taniguchi i, Saito F, Kikuchi K., Ogi H, Tanaka T, Katabuchi H, Nakayama H, Imamura T.	Enhancement of cancer invasion and growth via the C5a-C5a receptor system: Implications for cancer promotion by autoimmune diseases and association with cervical cancer invasion.	Oncology Letters	17	913-920	2019
Watanabe T, Mikami M, Katabuchi H, Kapan to S, Kaneuchi M, Takahashi M, Nakai H, Nagase S, Nii kura H, Mandai M, Hirashima Y, Yanai H, Yamagami W, Kamitani S, Higashi T.	Quality indicators for cervical cancer care in Japan	Journal of Gynecologic Oncology	29 (6)	e83	2019
Ebina Y, Mikami M, Nagase S, Tabata T, Kaneuchi M, Tashiro H, Mandai M, Enomoto T, Kobayashi Y, Katabuchi H, Yaegashi N, Udagawa Y, Aoki D	Japan Society of Gynecologic Oncology Guidelines 2017 for the Treatment of Uterine Cervical Cancer	Journal of Clinical Oncology	24	1-19	2019
大竹秀幸, 高石 清美, 宮原陽, 田代浩徳, 田中 信幸, 福間啓造, 宮村伸一, 片淵	平成28年熊本地震による 子宮がん検診事業への影響 に関する実態調査:震災後1 年目の報告	熊本産科婦人科 学会雑誌	63	39-45	2019

齋藤文誉, 片瀨秀隆	子宮体がんの標準治療	ライフライン 233 1 がんの先端医療		26-29	2019
境健爾, 岸裕人, 大竹秀幸, 濱口裕光, 吉田稔, 後藤慶次, 樋田直美, 内山恵美, 中川実優, 宮本伸枝, 江原美香, 安達美樹, 宇宿功市郎, 片瀨秀隆	熊本県におけるがん診療連携活動の現状と課題	癌と化学療法	46	1151-1157	2019
小寺千聡, 坂口勲, 大場隆, 片瀨秀隆	災害時小児・周産期の活動の実際と問題点 平成28年(2016年)熊本地震 産科	周産期医学	49	1241-1245	2019
Erdenebaatar C, Yamaguchi M, Saito F, Monsur M, Honda R, Tashiro H, Ohba T, Katabuchi H.	Administration of cabergoline contribute to preventing fertility in young hyperprolactinemic patients with endometrial cancer treated with medroxyprogesterone acetate.	International Journal of Gynecologic Cancer	28	539-544	2018
Saito T, Tabata T, Ikushima H, Yanai H, Tashiro H, Niihara H, Minaguchi T, Muramatsu T, Baba T, Yamagami W, Ariyoshi K, Ushijima K, Mikami M, Nagase S, Kaneuchi M, Yaegashi N, Udagawa Y, Katabuchi H.	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer	International Journal of Clinical Oncology	23	201-234	2018
Imamura Y, Tashiro H, Tsend-Ayush G, Haruta M, Dashdemberel N, Tsuboki J, Takashi K, Ohba T, Katabuchi H, Senju S.	Novel therapeutic strategies for advanced ovarian cancer with iPSC-derived myelomonocytic cells producing interferon beta.	Cancer Science	109	3403-3410	2018

Erdenebaatar C, Yamaguchi M, Saito F, Monsur M, Honda R, Tashiro H, Ohba T, <u>Katabuchi H.</u>	Administration of cabergoline contributes to preventing fertility in young hyperprolactinemic patients with endometrial cancer treated with medroxyprogesterone acetate.	International Journal of Gynecologic Cancer	28	539-544	2018
Mikami M, Shida M, Shibata T, <u>Katabuchi H.</u> , Kigawa J, Aoki D, Yaegashi N.	Impact of institutional accreditation by the Japanese Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer.	Journal of Gynecologic Oncology			2018 (online)
Mikami M, Ikeda M, Sato H, Iwase H, Enomoto T, Kobayashi Y, <u>Katabuchi H.</u>	The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan	Journal of Gynecologic Oncology			2018 (online)
Erdenebaatar C, Yamaguchi M, Monsur M, Saito F, Honda R, Tashiro H, Ohba T, <u>Katabuchi H.</u>	Serum prolactin contributes to enhancing prolactin receptor and pJAK2 in type I endometrial cancer cells in young women without insulin resistance	International Journal of Gynecologic Pathology			2018 (online)
宮原陽, <u>片瀨秀隆</u>	卵巣がん診療ガイドライン	腫瘍内科	21	448-453	2018
杉山徹, <u>片瀨秀隆</u> , 青木大輔	婦人科癌取り扱い規約の変更の経緯と要点	日本婦人科腫瘍学会雑誌	36	181-185	2018
永瀬智, 山上巨, 吉野潔, 徳永英樹, 齋藤俊章, <u>片瀨秀隆</u>	婦人科悪性腫瘍の登録事業と公共性	日本婦人科腫瘍学会雑誌	36	186-192	2018
境健爾, 安達美樹, 方尾志津, 山崎浩, 緒方美穂, 廣松矩子, 村上誠子, 中城加南子, 後藤慶次, 藤本真之介, 米田宏之, <u>片瀨秀隆</u>	熊本地震におけるがん診療連携拠点病院のがん相談支援センターの状況と課題	癌と化学療法	45	1311-1317	2018

境健爾, 安達美樹, 方尾志津, 山崎浩, 緒方美穂, 廣松矩子, 村上誠子, 中城加南子, 後藤慶次, 藤本真之介, 米田宏之, 片瀨秀隆	熊本地震におけるがん診療連携拠点病院のがん治療の状況と課題	癌と化学療法	45	1319-1325	2018
田代浩徳, 片瀨秀隆	「卵巢腫瘍取扱い規約」から「卵巢腫瘍・卵管癌・腹膜癌取扱い規約」- 背景と意義	癌の臨床	64	195-202	2018
Yamagami W, Nagase S, Takahashi F, Inoue K, Hachisuga T, Aoki D, Katabuchi H.	Clinical statistics of gynecologic cancers in Japan	Journal of Gynecologic Oncology	28	e32	2017
Shigeta S, Nagase S, Mikami M, Ikeda M, Shida M, Sakaguchi I, Ushioda N, Takahashi F, Yamagami W, Yaegashi N, Udagawa Y, Katabuchi H.	Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: A project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee	Journal of Gynecologic Oncology	28	e76	2017
Saito T, Takahashi F, Katabuchi H.	The 2016 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009	Journal of Obstetrics and Gynaecology Research	43	1667-1677	2017
Tayama S, Motohara T, Fujimoto K, Narantuya D, Sakaguchi I, Tashiro H, Saya H, Nagano O, Katabuchi H.	The impact of EpCAM on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer	Oncotarget	8	44312-44325	2017

Matsuo K, Shimada M, Yokota H, Satoh T, <u>Katabuchi H</u> , Kodama S, Sakasaka H, Matsumura N, Mikami M, Sugiyama T.	Effectiveness of adjuvant systemic chemotherapy for stage IB cervical cancer with intermediate risk factor	Oncotarget	8	106866-106875	2017
片瀨秀隆	産婦人科医の立場で行うティーンエイジからのがん教育	熊本県母性衛生学会雑誌	20	21-26	2017
大竹秀幸, 宮原陽, 高石清美, 田代浩徳, 福岡啓造, 田中信幸, 迫田芳生, 八木剛志, 片瀨秀隆	熊本県における子宮頸がん検診受診率向上への取り組みとその成果	九州連合産科婦人科学会雑誌	68	33-38	2017
Sunami E, Kusumoto T, Otsumi M, Sakamoto Y, Yoshida K, Tomita N, Muraeda A, Teshima J, Okabe M, Tanaka C, Yamauchi J, Ietabashi M, Koyake K, Takahashi K, Baba H, Boku N, <u>Aiba K</u> , Ishiguro M, Morita S, Takenaka N, Okude R, Sugihara K.	S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase II Superiority Trial.	Clin Colorectal Cancer	19(1)	22-31	2020
Iihara H, Shimokawa M, Herayashi T, Kawazoe H, Saeki T, <u>Aiba K</u> , Tamamura K.	A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan .	The Oncologist	24	1-8	2019
Yoshida I, Tamamura K, Miyamoto T, Shimokawa M, Takamatsu Y, Nanya Y, Matsumura I, Gotoh M, Igarashi T, Takahashi T, <u>Aiba K</u> , Kumagai K, Ishizawa K, Kurita N, Usui N, Hatake K.	Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subsequent Analysis in Japan.	In Vivo	33(4)	1355-1362	2019

Shimokawa M, Hayashi T, Kogawa T, Matsui R, Mizuno M, Kikkawa F, Saeki T, <u>Aiba K</u> , Tamura K.	Evaluation of combination antiemetic therapy on CINV in patients with gynecologic cancer receiving TC chemotherapy.	Anticancer Res	39(1)	225-230	2019
Nakazawa Y, Ando N, Harada D, Kitamura M, <u>Aiba K</u> , Kawakubo T.	Retrospective investigation of the risk factors for r sensitivity in panitumumab-induced hypomagnesemia.	Jpn J Cancer Chemother	45(10)	1435-1440	2018
Kusumoto T, Sunami E, Otsu M, Yoshida K, Sakamoto Y, Tomita N, Maeda A, Mochizuki I, Okabe M, Kunieda K, Yamauchi J, Itabashi M, Kotake K, Takahashi K, Baba H, Boku N, <u>Aiba K</u> , Ishiguro M, Morita S, Sugihara K.	Planned Safety Analysis of the ACTS-CC 02 Trial : A Randomized Phase Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage Colon Cancer.	Clin Colorectal Cancer	17(2)	e153-e161	2018
Suzuki K, Kobayashi N, Ogasawara Y, Shimada T, Yahatsugi Y, Sugiyama K, Takahara S, Saito T, Minami J, Yokoyama H, Kamiyama Y, Katsube A, Kondo K, Yanagisawa H, <u>Aiba K</u> , Yano S.	Clinical significance of cancer-related fatigue in multiple myeloma patients.	Int J Hematol	108(6)	580-587	2018

Oizumi S, Sugawara S, Minamoto K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Daimura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.	Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive <i>EGFR</i> mutations.	ESMO Open	23;3(2)	e000313. doi:10.1136/esmoopen-2017-000313. eCollection 2018	2018
Nishiwaki K, Sano K, Kamiyama Y, Hayashi K, Tanoue S, Katori M, Masuoka H, Aiba K.	Reduced-intensity umbilical cord blood transplantation for adult patients with fulminant aplastic anemia.	Rinsho Ketsueki	59(1)	64-68	2018
川島雅晴, 矢野真吾, 齋藤健, 横山洋紀, 町島智人, 矢萩裕一, 小笠原洋治, 杉山勝記, 高原忍, 南次郎, 神山祐太郎, 勝部敦史, 鈴木一史, 土橋史明, 薄井紀子, 相羽恵介.	チロシンキナーゼ阻害薬時代の慢性骨髄性白血病に対する同種骨髄移植の治療成績。	日本造血細胞移植学会誌	7	9-16	2018
西脇嘉一, 佐野公司, 神山祐太郎, 林和美, 田上晋, 香取美津治, 増岡秀一, 相羽恵介.	成人劇症型再生不良性貧血に対する強度減弱前処置を用いた非血縁者間臍帯血移植.	臨床血液	59(1)	64-68	2018
相羽恵介, 片濑秀隆.	日本癌治療学会の学術活動と社会連携活動	日本婦人科腫瘍学会雑誌	36(2)	118-123	2018
Baba Y, Baba H, Yamamoto S, Shimada H, Shibata T, Miyazaki T, Yoshikawa T, Nakajima Y, Tsujii Y, Shimokawa M, Kitagawa Y, Aiba K.	Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.	Dis Esophagus	30	1-7	2017

Mashima K, Yano S, Yokoyama H, Saito T, Machishima T, Shimada T, Yahagi Y, Takahara S, Sugiyama K, Ogasawara Y, Minami J, Kamiyama Y, Katsube A, Suzuki K, Ohshima S, Yamada H, Usui N, Aiba K.	Epstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature Review.	Intern Med	56	701-706	2017
Kusumoto T, Sunami E, Otake M, Yoshida K, Sakamoto Y, Tomita N, Maxeda A, Mochizuki I, Okabe M, Kunieda K, Yamauchi J, Itabashi M, Kerotake K, Takahashi K, Baba H, Boku N, Aiba K, Ishiguro M, Morita S, Sugihara K	Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.	Clin Colorectal Cancer	pii: S1533-0028(17)30161-5. doi:		2017
Matsumoto A, Nishikawa K, Yuda M, Tanaka Y, Tanishima Y, Arakawa Y, Ishibashi Y, Sakuyama T, Omura N, Mitsumori N, Aiba K, Yanagawa K.	Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study.	Anticancer Res	36	1937 - 1942	2017
Arakawa Y, Tamura M, Aiba K, Morikawa K, Aizawa D, Ikegami M, Yuda M, Nishikawa K.	Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer : A case report.	Oncol Lett	14	3039-3042	2017
相羽恵介	内科懇話会 がん薬物療法における支持療法の進歩	日本医事新報	4853	42-49	2017

林和美, 相羽恵介	貧血学-最新の診断・治療動向、二次性貧血 慢性疾患に伴う貧血(ACD) ACDと基礎疾患の関わり 悪性腫瘍	日本臨床	75(1)	528-531	2017
相羽恵介	いつ・誰に尋ねられてももう困らない!がん化学療法薬の知識アップデート すぐに役立つ最新 Q&A 抗がん薬の投与方法 Q&A 腎機能障害に伴う抗がん薬の減量投与	月刊ナーシング	37	66 -67	2017
大場理恵, 薄井紀子, 伊藤勇太, 山内浩文, 町島智人, 石井敬人, 福島僚子, 横山洋紀, 塩田祐子, 矢萩裕一, 矢野真吾, 土橋史明, 相羽恵介	Azacitidine 治療が奏効し臍帯血移植を施行した骨髄線維化を伴う骨髄異形成症候群 .	臨床血液	58	601-606	2017
高原忍, 相羽恵介	これだけは押さえておきたい がん化学療法薬の薬 抗がん剤・ホルモン剤・分子標的薬・支持療法薬 はや調べノート 2017・2018 年版 ざっくり解説!支持療法薬 悪心・嘔吐対策薬 .	プロフェッショナルがんナーシング	2017 別冊	218-220	2017
伊藤勇太, 野田健太郎, 相羽恵介, 矢野真吾, 藤井常宏	Pegfilgrastim 投与後に薬剤誘発性血管炎を発症したびまん性大細胞型 B 細胞リンパ腫	臨床血液	58	2238-2242	2017
Yamanaka T, Harimoto N, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Handa T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanaabe A, Kubo N, Araki K, Shirabe K.	Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts.	Br J Cancer	in press		2020
Kubo N, Shirabe K.	Treatment strategy for isolated bile leakage after hepatectomy: Literature review.	Ann Gastroenterol Surg	4(1)	47-55	2019

Igarashi T, Shimizu K, Usui K, Yokobori T, Ohtaki Y, Nakazawa S, Obayashi K, Yajima T, Nobusawa S, Ohkawa T, Katoh R, Motegi Y, Ogawa H, Harimoto N, Ichihara T, Mitani Y, Yokoo H, Mogi A, <u>Shirabe K.</u>	Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer.	Int J Clin Oncol	in press		2019
Kurozumi S, Inoue K, Matsushima H, Fujii T, Horiguchi J, Oyama T, Kurozumi M, <u>Shirabe K.</u>	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.	Sci Rep	9(1)	16662	2019
Yokobori T, Yazawa S, Asao T, Nakazawa N, Mogi A, Sawano R, Kuwano H, Kaira K, <u>Shirabe K.</u>	Fucosylated α 1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer.	Sci Rep	9(1)	14503	2019
Harimoto N, Hoshino K, Mifuranushi R, Hiragawa K, Yamamaka T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Hosouchi Y, Suzuki H, Arakawa K, Hirai K, Fukazawa T, Ikota H, <u>Shirabe K.</u>	Prognostic significance of Mf neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.	Pancreatology	19(6)	897-902	2019

Ishii N, Harimoto N, Araki K, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Yamanaka T, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, <u>Shirabe K.</u>	Preoperative Mac-2 binding protein glycosylation isomer level predicts postoperative ascites in patients with hepatic resection for hepatocellular carcinoma.	Hepatol Res	49(12)	1398-1405	2019
Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, <u>Shirabe K.</u> Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA.	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.	Br J Cancer	120(12)	1129-1136	2019
Igarashi T, Harimoto N, Matsumura N, Sugiyama M, Araki K, Yokobori T, Kosone T, Takagi H, Aishima S, Yokoo H, <u>Shirabe K.</u>	Fairly rare small-diameter hepatocellular carcinoma with right adrenal gland metastasis having an inferior vena cava tumor thrombus: a case report.	Surg Case Rep	5(1)	170	2019
Igarashi T, Harimoto N, Nobusawa S, Yoshida Y, Yamanka T, Hagiwara K, Hoshino K, Ishii N, Tsukagoshi M, Watanabe A, Kubo N, Araki K, Yokobori T, Yokoo H, <u>Shirabe K.</u>	Evaluation of KRAS Mutation Status in a Patient With Concomitant Pancreatic Neuroendocrine Neoplasm and Intraductal Papillary Mucinous Neoplasm.	Pancreas	48(5)	e34-e35	2019

Harimoto N, Hoshino H, Muranushi R, Hagiwara K, Yamamoto T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Araki K, <u>Shirabe K</u> .	Skeletal Muscle Volume and Intramuscular Adipose Tissue Are Prognostic Predictors of Postoperative Complications After Hepatic Resection.	Anticancer Res	38(8)	4933-4939	2018
Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsalem M, Alsaed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, <u>Shirabe K</u> , Martin SG, Ellis IO, Green AR, Rakha EA.	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.	Breast Cancer Res Treat	172(1)	61-68	2018
Harimoto N, Yoshizumi T, Inokuchi S, Itoh S, Adachi E, Ikeda Y, Uchiyama H, Utsunomiya T, Kajiyama K, Kimura K, Kishihara F, Sugimachi K, Tsujita E, Ninomiya M, Fukuzawa K, Maeda T, <u>Shirabe K</u> , Maehara Y.	Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study.	Ann Surg Oncol	25(11)	3316-3323	2018
Sano A, Sakurai S, Komine C, Tabe Y, Saito K, Fukasawa T, Kiriya S, Yamamoto H, Tani M, Naitoh H, <u>Shirabe K</u> , Kuwano H.	Paget's disease derived in situ from reserve cell hyperplasia, squamous metaplasia, and squamous cell carcinoma of the esophagogastric junction: a case report.	Surg Case Rep	4(1)	81	2018

Hagiwara K, Araki K, Yamamoto T, Ishii N, Igarashi T, Watanabe A, Kubo N, Harimoto N, Kuwano H, Nobusawa S, Aishima S, <u>Shirabe K.</u>	Resected primary mucinous cholangiocarcinoma of the liver.	Surg Case Rep	4(1)	41	2018
<u>Shirabe K</u> , Bekki Y, Gantumur D, Araki K, Ishii N, Kuwano A, Narimatsu H, Mizokami M.	Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.	J Gastroenterol	53(7)	819-826	2018
Araki K, Kubo N, Watanabe A, Kuwano H, <u>Shirabe K.</u>	Systematic review of the feasibility and future of laparoscopic liver resection for difficult lesions.	Surg Today	48(7)	659-666	2018
Tsukagoshi M, Araki K, Saito F, Kubo N, Watanabe A, Igarashi T, Ishii N, Yamanaka T, <u>Shirabe K</u> , Kuwano H.	Evaluation of the International Consensus Guidelines for the Surgical Resection of Intraductal Papillary Mucinous Neoplasms.	Dig Dis Sci	63(4)	860-867	2018
Ishii N, Araki K, Yamanaka T, Handa T, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Aishima S, Kuwano H, <u>Shirabe K.</u>	Small cholangiolocellular carcinoma that was difficult to distinguish from cholangiocellular carcinoma: a case report.	Surg Case Rep	3(1)	103	2017
Yanoma T, Ogata K, Yokobori T, Ide M, Mochiki E, Toyomasu Y, Yanai M, Kogure N, Kimura A, Suzuki M, Nakazawa N, Bai T, Oyama T, Asao T, <u>Shirabe K</u> , Kuwano H.	Heat shock-induced HIKESHI protects cell viability via nuclear translocation of heat shock protein 70.	Oncol Rep	38(3)	1500-1506	2017

渡邊清高	医療健康報道の質を探る メディアドクターで記事を 「科学」する.	日本ヘルスコミ ュニケーション 学会雑誌	Sep; 28	Web	2019
渡邊清高, 有賀 悦子, 橋本俊一, 堀江大輔, 坂本 義一, 小澤盛博, 坂井元, 渡邊友 浩, 田中由紀, 武田忠利, 関順 彦	帝京大学中学校・高等学校 における中学1年生を対象 としたがん教育授業	帝京医学雑誌	42(2)	51-60	2019
大坂巖, 渡邊清 高, 志真泰夫, 倉持雅代, 谷田 憲俊	わが国におけるWHO緩和 ケア定義の定訳 デルファ イ法を用いた緩和ケア関連 18団体による共同作成	Palliative Care Research	14(2)	61-66	2019
Natsume M, Watanabe K, Matsumoto S, Naruge D, Ha yashi K, Furu se J, Kawamu ra M, Jinno H, Sano K, Fu kushima R, Os awa G, Aruga E, Hashiguch i Y, Tanaka A, Takikawa H, Seki N.	Factors Influencing Can cer Patients' Choice of End-of-Life Care Place.	J Palliat Med	21(6)	751-765	2018